Please assess the completion status of the following clinical trial:

Trial Title: The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960).~* Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study.~Exclusion Criteria:~* Patients with bipolar I or bipolar II disorder~* Patients with personality disorders~* Patients with eating disorders~* Patients with substance dependence or abuse~* Patients with concurrent active medical condition~* Patients with history of seizures~* Patients with history of receiving Electroconvulsive therapy (ECT)~* Patients with diabetes and other inflammatory disorders~* Patients with allergy or contraindications to the used medications~* Patients with finally pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
- Metformin group (Type: EXPERIMENTAL): Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).